sglt2 inhibitors vs glp 1 agonists Effect of combination treatment with glucagon-like peptide-1 receptor and sodium-glucose cotransporter-2 on incidence of cardiovascular and serious renal events: population based cohort study GLP-1 receptor agonists and SGLT2

Back Zunz E, La Barre, J (1929) 'Contributions a l'tude des variation physiologiques de la scrtion interne de pancras: relations entre les secretions externe et interne du pancras', Archives Internationales Physiolologie et de Biochimie , 31/1, 20-44

Lightweight builds that respect battery life and data usage frequently win the day, especially for commuters or anyone juggling short play windows between daily tasks

doi: 10.1111/dom.16316

For patients primarily seeking weight management, either with or without type 2 diabetes, higher-dose formulations such as semaglutide 2.4 mg (Wegovy) or liraglutide 3 mg (Saxenda) may be more appropriate

Discontinuation of GLP-1 therapy may result in weight regain and recurrence of hepatic steatosis, emphasizing the need for long-term treatment strategies